PTGX Protagonist Therapeutics, Inc.
$138.69 -1.38%
US Stock · Health Care
RSI (14) · 30 / 70 bands
MACD (12, 26, 9)
Solid = close · dashed = 50-day MA · bars = volume. Toggle Bollinger / RSI / MACD. Hover to inspect. EOD data.
1D
-1.38%
YTD
+111.80%
P/E
108.57
P/B
8.88
ROE
12%
Div yield
—
Beta
0.2
Market cap
$9.0B
RSI (14)
42
Next earnings
Nov 4, 2026
Previous session
close of Oct 6, 2026 · EOD, no live order bookOpen
$140.34
Close
$138.69
VWAP (n/a)
—
Day high
$141.00
Day low
$136.09
Volume
636K
VWAP = daily turnover ÷ volume — the volume-weighted average, the closest EOD read on where trading actually clustered. A true order book is live-only and needs a broker feed. Turnover/VWAP available for MOEX listings.
Latest headlines
Protagonist Therapeutics Announces $300 Million Share Repurchase Program
Yahoo Finance · Sep 8
Protagonist (PTGX) Swings To A Profit As Two Drugs Near Blockbuster Status
Yahoo Finance · Sep 6
MIMRYLO Approval Triggered $275M Payments for Protagonist (PTGX). Are Royalties the Better Commercial Model?
Yahoo Finance · Sep 4
The Bull Case For Protagonist Therapeutics (PTGX) Could Change Following FDA Approval Of MIMRYLO And Takeda Milestones
Yahoo Finance · Sep 1
Protagonist Therapeutics (PTGX) Could Be 63% Below Fair Value After Investor Update Call
Yahoo Finance · Sep 1
Protagonist Wins FDA Approval for MIMRYLO in Rare Blood Cancer Treatment
Yahoo Finance · Aug 31
Headlines via Yahoo Finance · links open the source · not an endorsement.
Recent SEC filings
10-Q Aug 5, 2026 View → 8-K Aug 5, 2026 View → 8-K Jun 18, 2026 View → 10-Q May 5, 2026 View → 8-K May 5, 2026 View →
Source: SEC EDGAR · opens the official filing.
Research & reports
External resources — availability and opinions are theirs, not ours.
This is reference data for your own analysis — not a recommendation to buy or sell PTGX. Try it in the Lab to size a position and see the risk.